Medication

Photo

Know your enemy

Along with MRSA and ESBL bacteria, Clostridium difficile is causing a growing problem. Epidemics of a new C. difficile strain have already occurred in hospitals in North America, England and the Benelux countries.

Photo

MRSA in US hospitals

Arlington Medical Resources (AMR), a pharmaceutical market research firm, found that the number of patients treated with an antibiotic associated with MRSA-infections within U.S. acute care hospitals has increased 8 percent by the last year. But the average time MRSA-patients had to stay in hospital decreased by 10 percent.

New drug protects against venous blood clots

In the EU blood clots are responsible for killing 544.000 people each year. Rivaroxaban, a new oral given anticoagulant drug from Bayer Healthcare, is significantly more effective than the current standard of care, according to three recent studies. The number of blood cluts in Europe is about 1.5 million per year, more than thirty percent of the patients affected die.

Photo

TI: Corruption and fraud in the German healthcare system

The German chapter of anti-corruption organisation Transparency International had another close look at the German healthcare system. And it didn't like what it found: In an updated policy paper, member of the board of directors Anke Martiny, deplores that "huge amounts of money belonging to the insured are lost" due to lack of transparency, to corruption and fraud.

Inhaled TB vaccine

USA - A new tuberculosis vaccine successfully tested at the University of North Carolina (UNC) is easier to administer and store and just as effective as one commonly used worldwide, according to research published in the Proceedings of the National Academy of Sciences.

On the near horizon

The first FDA-approved prescription medication that reduces blood phenylalanine (Phe) levels in patients with Phenylketonuria (PKU) — a genetic disorder that prevents the normal use of protein foods and can lead to impaired brain development if untreated — could result in more regular screening of blood phenylalanine (Phe) levels in PKU patients.

Photo

Improvement to therapeutic effects for seasonal rhinitis

Patients suffering from moderate to severe seasonal allergic rhinitis experience significantly improved therapeutic effects when combining nasal Azelastine spray with Fluticason nasal spray as opposed to using Fluticason nasal spray by itself. Those are the surprising results of a study released by the Annals of Allergy & Asthma Immunology (1) in January 2008. Azelastine is a first-line,…

Photo

COPD: New therapy reduces mortality

Patients with severe COPD may benefit more from therapy that combines salmeterol and fluticasone [SFC] than treatment with tiotropium, according to results from a long-term, multi-center study, “Investigating New Standards for Prophylaxis in Reducing Exacerbations” (INSPIRE) that directly compared the two therapies.

Photo

Neuroendocrine Cancer

The collaboration between two companies may pave the way for the development of new therapy options for neuroendocrine tumors: Covidien LTd, a global provider of healthcare products and BioSynthema Inc., a company specialized in the discovery and development of molecular targeted biophamaceuticals recently signed an agreement that will gain BioSynthema access to specific Covidien proprietary…

Starving a tumour

Every developing tissue is supplied by blood vessels with oxygen and nutrients. Tumours grow far more quickly than normal tissues, so have a greater need of nutrients, which is why tumour cells begin to produce growth factors that stimulate the formation of blood vessels.

70 show more articles
Subscribe to Newsletter